Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6;9(1):21.
doi: 10.1186/s41181-024-00250-6.

Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET

Affiliations

Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET

Eva Schlein et al. EJNMMI Radiopharm Chem. .

Abstract

Background: The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of antibody-based ligands through the blood-brain barrier (BBB). To overcome this physiological obstacle, we have previously developed bispecific antibody ligands that pass through the BBB via receptor-mediated transcytosis. While these radiolabelled ligands have high affinity and specificity, their long residence time in the blood and brain, typical for large molecules, poses another challenge for PET imaging. A viable solution could be a two-step pre-targeting approach which involves the administration of a tagged antibody that accumulates at the target site in the brain and then clears from the blood, followed by administration of a small radiolabelled molecule with fast kinetics. This radiolabelled molecule can couple to the tagged antibody and thereby make the antibody localisation visible by PET imaging. The in vivo linkage can be achieved by using the inverse electron demand Diels-Alder reaction (IEDDA), with trans-cyclooctene (TCO) and tetrazine groups participating as reactants. In this study, two novel 18F-labelled tetrazines were synthesized and evaluated for their potential use as pre-targeting imaging agents, i.e., for their ability to rapidly enter the brain and, if unbound, to be efficiently cleared with minimal background retention.

Results: The two compounds, a methyl tetrazine [18F]MeTz and an H-tetrazine [18F]HTz were radiolabelled using a two-step procedure via [18F]F-Py-TFP synthesized on solid support followed by amidation with amine-bearing tetrazines, resulting in radiochemical yields of 24% and 22%, respectively, and a radiochemical purity of > 96%. In vivo PET imaging was performed to assess their suitability for in vivo pre-targeting. Time-activity curves from PET-scans showed [18F]MeTz to be the more pharmacokinetically suitable agent, given its fast and homogenous distribution in the brain and rapid clearance. However, in terms of rection kinetics, H-tetrazines are advantageous, exhibiting faster reaction rates in IEDDA reactions with dienophiles like trans-cyclooctenes, making [18F]HTz potentially more beneficial for pre-targeting applications.

Conclusion: This study demonstrates a significant potential of [18F]MeTz and [18F]HTz as agents for pre-targeted PET brain imaging due to their efficient brain uptake, swift clearance and appropriate chemical stability.

Keywords: Alzheimer’s disease; Bioorthogonal; Fluorine-18; IEDDA; Inverse electron demand Diels–Alder reaction; PET; Pre-targeting; TCO; Tetrazine; Trans-cyclooctene.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Scheme 1
Scheme 1
[18F]Fluoride was trapped on a Chromabond PS-HCO3 cartridge and dried with acetonitrile. a The precursor Py-TFP 3 in acetonitrile was reacted with the [18F]fluoride on the solid support and the formed [18F]F-Py-TFP 4 ester eluted from the cartridge. Unreacted precursor Py-TFP 3 was removed by an Oasis MCX Plus cartridge. b The labelled tetrazines [18F]MeTz 6a and [18F]HTz 6b were synthesized by direct amidation
Scheme 2
Scheme 2
a 6-fluoronicotinic acid was reacted with TFP and N,N-dicyclohexylcarbodiimide in acetonitrile over night at RT to form 6-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester b The reference compounds were synthetized by direct amidation
Fig. 1
Fig. 1
Radiochemical purity of A [18F]MeTz and B [18F]HTz measured over 180 min. The stability test in PBS was performed for [18F]HTz in the presence of ascorbic acid as stabilizer and for [18F]MeTz without ascorbic acid
Fig. 2
Fig. 2
PET images of [18F]MeTz and [18F]HTz obtained in tg-ArcSwe animals. The images represent the first five min and the last 10 min of the respective scan
Fig. 3
Fig. 3
Time-activity curves of selected brain regions of [18F]MeTz and [18F]HTz. A [18F]MeTz 0.43 ± 0.12 MBq/g mouse and B [18F]HTz 0.38 ± 0.06 MBq/gmouse. C Comparison of whole brain [18F]MeTz and [18F]HTz TACs. D Biodistribution post-mortem

Similar articles

References

    1. Battisti UM, Bratteby K, Jørgensen JT, Hvass L, Shalgunov V, Mikula H, et al. Development of the first aliphatic 18F-labeled tetrazine suitable for pretargeted PET imaging - expanding the bioorthogonal tool box. J Med Chem. 2021;64(20):15297–15312. doi: 10.1021/acs.jmedchem.1c01326. - DOI - PubMed
    1. Bredack C, Edelmann MR, Borroni E, Gobbi LC, Honer M. Antibody-based in vivo imaging of central nervous system targets—evaluation of a pretargeting approach utilizing a TCO-conjugated brain shuttle antibody and radiolabeled tetrazines. Pharmaceuticals. 2022;15(12):1445. doi: 10.3390/ph15121445. - DOI - PMC - PubMed
    1. Chang C-Y, Chen J-Y, Ke D-S. Essential fatty acids and human brain. Acta Neurol Taiwan. 2009;18:231–241. - PubMed
    1. Cheung P, Thorngren J, Zhang B, Vasylovska S, Lechi F, Persson J, et al. Preclinical evaluation of Affibody molecule for PET imaging of human pancreatic islets derived from stem cells. EJNMMI Res. 2023;13(1):1–12. doi: 10.1186/s13550-023-01057-3. - DOI - PMC - PubMed
    1. Chomet M, Van Dongen GAMS, Vugts DJ. State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET. Bioconjug Chem. 2021;32(7):1315–1330. doi: 10.1021/acs.bioconjchem.1c00136. - DOI - PMC - PubMed

LinkOut - more resources